Stocktoria
Aligos Therapeutics, Inc. ALGS
Aligos Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 | $0 | — |
| R&D expense | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M | $79.9M | $44.0M |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M | -$97.8M | -$54.0M |
| Income tax | $314,000 | $331,000 | $795,000 | $106,000 | $143,000 | $161,000 | $85,000 |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M | -$108.5M | -$52.3M |
| EPS (diluted) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | — | — | — |
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M | -$74.3M | -$46.8M |
| Free cash flow | — | -$80.9M | -$79.0M | -$80.3M | -$116.6M | -$76.3M | -$49.6M |
| Cash & equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M | $220.4M | $69.6M |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M | $265.3M | $146.5M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M | $45.3M | $29.3M |
| Shareholders' equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M | $220.0M | -$64.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -39.5% | -41.7% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.